Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Monday, up 5.64% from the previous trading day, before settling in for the closing price of $12.77. Over the past 52 weeks, MLYS has traded in a range of $6.38-$16.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -85.50%. With a float of $23.53 million, this company’s outstanding shares have now reached $49.76 million.
Let’s determine the extent of company efficiency that accounts for 28 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 52.72%, while institutional ownership is 49.44%. The most recent insider transaction that took place on Nov 11 ’24, was worth 75,398. In this transaction Chief Medical Officer of this company sold 5,026 shares at a rate of $15.00, taking the stock ownership to the 140,991 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Officer proposed sale 5,026 for $15.00, making the entire transaction worth $75,398.
Mineralys Therapeutics Inc (MLYS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -85.50% per share during the next fiscal year.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 8.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.27, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Looking closely at Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days average volume was 0.21 million, which is a jump from its year-to-date volume of 0.18 million. As of the previous 9 days, the stock’s Stochastic %D was 79.12%. Additionally, its Average True Range was 0.87.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 73.61%, which indicates a significant increase from 63.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.55% in the past 14 days, which was higher than the 71.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.16, while its 200-day Moving Average is $12.81. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $14.28. Second resistance stands at $15.07. The third major resistance level sits at $15.96. If the price goes on to break the first support level at $12.61, it is likely to go to the next support level at $11.72. Now, if the price goes above the second support level, the third support stands at $10.93.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 653.97 million has total of 49,769K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -71,900 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -56,340 K.
